A recent study published in Adipocyte explored the short-term safety and preliminary efficacy of sodium pentaborate pentahydrate (NaB) in adults with overweight and obesity. This randomized, double-blind, placebo-controlled, phase 1/2 trial evaluated the effects of varying doses of NaB (200-1,000 mg) over a 12-week period with 177 participants, of whom 116 completed the trial.
# Study Findings
The study reported no major short-term safety signals across all dose groups. Significant reductions in body weight and body mass index (BMI) were observed at the highest dose (1,000 mg), with mean body weight decreasing by 2.30 kg (p = 0.01) and BMI by 0.85 kg/m² (p = 0.02) compared to placebo. All adverse events were classified as mild, supporting the short-term safety of NaB.
# Study Design and Limitations
This study is classified as a phase 1/2 randomized controlled trial (PMID: 42634930, DOI: 10.1080/21623945.2026.2716431). While demonstrating promising short-term results, this trial requires confirmation through more extensive phase 3 trials to explore long-term effects and broader applicability.
# Conclusion
Sodium pentaborate pentahydrate may offer a potential intervention for weight management in obesity. However, further research is necessary to fully understand its long-term safety and efficacy. The trial's short-term nature is a limitation that future studies must address.